Asthma
Conditions
Keywords
Double-blind, Randomized, Dose-escalating, Placebo-controlled, Phase I, Healthy volunteers, Bronchial asthma, Histamine glutarimide, EURRUS
Brief summary
The study focusses on the evaluation of safety and tolerability of the XC8. The design of the study involves sequential dosing of cohorts (group of volunteers), taking increasing doses of the product after receiving conclusion and recommendation for further continuation of the study from the Dose Escalation Committee.
Interventions
DRUGXC8 (histamine glutarimide)
DRUGPlacebo
Sponsors
EURRUS Biotech GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men and women aged 18 to 50 years; 2. Generally good health; 3. Body mass index of 19 to 30 kg/m² and \>50 kg body weight; 4. Female subjects who are post-menopausal (no menstrual period for a minimum of 1 year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practice a highly effective method of birth control, i.e. resulting in a failure rate of less than 1% per year when used consistently and correctly (e.g. implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence, or vasectomized partner). The birth control method must have been applied for at least 1 cycle before and until 3 months after administration of the study medication. 5. Male subjects with a female partner of child-bearing potential agree to use a medically acceptable method of contraception (e.g. condoms, sexual abstinence, vasectomy) during the study, and until 3 months after the last intake of study medication. 6. Subjects are willing and able (in the opinion of the investigator) to understand and comply with the procedures and evaluations of the study. 7. Subjects must be willing and legally able to give written informed consent.
Exclusion criteria
1. Hepatic or renal disease; any other disease, which may influence the clinical trial results or may lead to health worsening during the trial (according to the investigator's opinion); 2. Clinically significant laboratory abnormalities; 3. Use of any medication, including prophylaxis, within 1 month before screening (including herbal preparations and nutritional supplements); 4. Positive test for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus HBV at Screening; 5. Irregular sleep (e.g. night work, sleep disturbances, insomnia, returning from another time zone, etc.); 6. History or current evidence of alcohol or drug abuse; alcohol or drug intake within 4 days before Screening; 7. History or current evidence of allergic reactions (including reactions to medications and food); 8. History or current evidence of symptomatic rhinitis within 2 years before Screening (allergic rhinitis, non-allergic rhinitis, or hay fever, excluding short-term viral infection - cold or influenza); 9. Blood or plasma donation, or surgery (in hospital) within 12 weeks of Screening; 10. Lactating or pregnant females; a positive pregnancy test before the first administration of investigational medicinal product or breastfeeding; 11. Current or previous (within 3 months of enrollment) treatment with another investigational drug and/or medical device or participation in another clinical study; 12. Previous enrollment in this clinical study; 13. Inability to understand or follow protocol instructions; 14. Smoking within 3 months before screening or throughout the study; 15. Lactose intolerance; 16. History of allergic reactions to XC-8 or any inactive ingredients of the trial medication; 17. Employees of the sponsor or subjects who are employees or relatives of the investigator;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse events per treatment arm | Change from pre-dose up to Day 36 | Adverse events will be summarized descriptively by treatment arm. Verbatim terms will be mapped to preferred terms and organ systems using the current Medical Dictionary for Regulatory Activities version. For each preferred term, frequency counts and percentages will be calculated by cohort.The nature, severity, seriousness, and relationship to study medication will be summarized for all study subjects |
| Laboratory data | Changes from Day 1 (pre-dose) till Day 2 | Laboratory data (hematology, biochemistry and urinalysis) will be summarized by treatment arm. Changes from pre-dose will be presented using shift tables (employing the categories 'normal', 'abnormal, clinically not significant' and 'abnormal, clinically significant') and absolute changes in laboratory values, if appropriate. |
| Physical examination | Day 1 | Physical examination results will be listed for following: general appearance, skin, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest, heart, abdomen (including liver examination), extremities, and nervous system. |
| 12-lead ECG | Change from pre-dose till Day 2 | 12-lead ECG results will be analyzed descriptively |
| Vital signs | Changes from pre-dose till Day 36 | Vital signs (blood pressure, respiratory rate, pulse, and temperature) results will be analyzed descriptively. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of XC8 by assessing Tmax | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Time to reach Cmax |
| Pharmacokinetics of XC8 by assessing λz | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Apparent first order terminal elimination rate constant |
| Pharmacokinetics of XC8 by assessing t1/2 | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Terminal elimination half-life |
| Pharmacodynamic analyses: blood eosinophils | changes from Day 1 (pre-dose) to Day 2 and Day 8 (pre-dose) to Day 22 | — |
| Pharmacodynamic analyses: blood cytokines | changes from Day 1 (pre-dose) to Day 2 and Day 8 (pre-dose) to Day 22 | — |
| Pharmacokinetics of XC8 by assessing Cav | Day 8 to 11, 13 and 15 (Pre dose); Day 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 22 (24 hours ±10 minutes post dose) | Average concentration over one dosing interval |
| Pharmacokinetics of XC8 by assessing AUCinf | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Area under the plasma concentration-time curve extrapolated to infinity |
| Pharmacokinetics of XC8 by assessing Cmax | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Maximum plasma concentration |
| Pharmacokinetics of XC8 by assessing AUC0-tlast | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Area under the plasma concentration-time curve up to the last sampling time with a concentration above the limit of quantification |
| Pharmacokinetics of XC8 by assessing AUC0-24 | Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4 and 8 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose); Day 8 to 11, 13 and 15 (Pre dose) | Area under the plasma concentration-time curve up to 24 hours after study drug administration |
Countries
Austria, Germany
Outcome results
None listed